吉西他滨联合方案在治疗复发难治性非霍奇金淋巴瘤中的疗效观察

Efficacy of gemcitabine plus program in the treatment of relapsed or refractory non-Hodgkin's lymphoma

目的探讨吉西他滨联合方案治疗复发难治性非霍奇金淋巴瘤的临床疗效。方法 选择2011年6月-2016年1月期间我院收治的106例复发难治性非霍奇金淋巴瘤患者,将所有患者按照治疗方法分为观察组和对照组,各53例。观察组用吉西他滨联合方案治疗（吉西他滨、奥沙利铂、地塞米松）,对照组用CHOP化疗方案进行治疗,一个周期为21 d,疗效的评定于两个周期后进行。比较两组患者的临床疗效及毒副作用发生情况。结果 观察组RR高于对照组,差异有统计学意义（P〈0.05）。观察组白细胞减少、血小板减少、发热、消化道反应及其他不良反应发生率低于对照组,差异有统计学意义（P〈0.05）;观察组贫血、周围神经毒性发生率与对照组比较,差异无统计学意义（P〉0.05）。结论 复发难治性非霍奇金淋巴瘤采用吉西他滨联合方案治疗有一定疗效,毒副反应较轻微,患者可耐受。

Objective To investigate the clinical effect of joint program of gemcitabine in the treatment of relapsed or refractory non-Hodgkin＇s lymphoma. Methods 106 cases of CPC relapsed or refractory non-Hodgkin＇s lymphoma patients were selected from June 2011 to January 2016 in our hospital, all the patients were divided into observation group （n=53） and control group （n=53） according to the treatment methods. Patients in observation group were treated with gemcitabine in combination with chemotherapy（gemcitabine, oxaliplatin, dexamethasone）, and the control group was treated with CHOP regimen therapy, the treatment period was 21 d, the clinical effect was assessed after two cycles. The efficacy and toxic side effect of two groups were compared. Results RR of the observation group was higher than that of control group, the difference was statistically significant（P〈0.05）. The incidence of leukopenia, thrombocytopenia, fever, gastrointestinal reactions and other relatively adverse reactions incidence in the observation group were lower than that of control group, the differences were statistically significant（P〈0.05）; while the incidence of anemia, peripheral neurotox- icity in the observation group were relatively little difference in the control group, there were no statistically significant difference between the two groups （/9〉0.05）. Conclusion Gemcitabine plus program has a certain effect on relapsed or refractory non-Hodgkin＇s lymphoma, mild toxicity, and the patient can tolerate.